Journal
ADVANCED FUNCTIONAL MATERIALS
Volume 27, Issue 32, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.201700919
Keywords
advanced therapies; nanoparticles; protein materials; self-assembly; therapeutic proteins
Categories
Funding
- MINECO [BIO2013-41019-P]
- AGAUR [2014SGR-132]
- CIBER de Bioingenieria, Biomateriales y Nanomedicina (Project NANOPROTHER)
- Marato de TV3 foundation [TV32013-3930]
- FIS [PI15/00272]
- ISCIII [PI15/00378, PIE15/00028]
- FEDER
- Marato TV3 [2013-2030]
- Miguel Servet contract
- AGAUR (FI-DGR)
- [AGAUR2014-PROD0005]
Ask authors/readers for more resources
Protein materials are gaining interest in nanomedicine because of the unique combination of regulatable function and structure. A main application of protein nanoparticles is as vehicles for cell-targeted drug delivery in the form of nanoconjugates, in which a conventional or innovative drug is associated to a carrier protein. Here, a new nanomedical approach based on self-assembling protein nanoparticles is developed in which a chemically homogeneous protein material acts, simultaneously, as vehicle and drug. For that, three proapoptotic peptidic factors are engineered to self-assemble as protein-only, fully stable nanoparticles that escape renal clearance, for the multivalent display of a CXCR4 ligand and the intracellular delivery into CXCR4(+) colorectal cancer models. These materials, produced and purified in a single step from bacterial cells, show an excellent biodistribution upon systemic administration and local antitumoral effects. The design and generation of intrinsically therapeutic protein-based materials offer unexpected opportunities in targeted drug delivery based on fully biocompatible, tailor-made constructs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available